ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell



    
    Commercial License to Accelerate Development of New Hemostasis
    Breakthrough Products
    

    LEIDEN, The Netherlands, Jan. 13 /CNW/ - ProFibrix B.V., today announced
that it has concluded a commercial license agreement with Crucell N.V.
(Euronext, NASDAQ:   CRXL; Swiss Exchange: CRX) for PER.C6(R), a unique human
protein production platform. The PER.C6(R) platform allows ProFibrix to
manufacture recombinant human fibrinogen at levels that support the
development and commercial roll-out of new products. Fibrinogen is at the
heart of all ProFibrix products and is an essential part of nature's own
injury-repair mechanism. The company's lead product Fibrocaps(TM) is based on
fibrinogen derived from human blood plasma and is a unique dry powder topical
hemostat that stops acute and severe bleeding during surgery or after trauma
injury. Initially recombinant fibrinogen will be developed for systemic
applications in hemostasis and later on for the development of tissue repair
products.
    Jaap Koopman, Ph.D., Chief Executive Officer, said: "The PER.C6(R)
license gives us access to a manufacturing platform that has already been
successfully tested by ProFibrix for high expression of biologically active
recombinant fibrinogen. Our Chief Technology Officer Dr. Bram Bout was one of
the inventors of PER.C6(R) while at Crucell. His intimate knowledge of the
platform in combination with our substantial in-house expertise on the biology
of fibrinogen provides us with a strong competitive position in the hemostasis
market."
    Jan Ohrstrom, MD, Chief Operational Officer, said: "We believe
recombinant fibrinogen has the potential to become a breakthrough product in
hemostasis and tissue repair. We intend to develop a systemic hemostat product
based on recombinant fibrinogen to treat or prevent bleeding in patients with
low fibrinogen levels."

    About ProFibrix

    ProFibrix was founded in 2004 and is headquartered in Leiden, The
Netherlands, with a subsidiary in Seattle, WA. The company leverages its
expertise in fibrinogen technology to develop and market innovative products
for the hemostasis and regenerative medicine markets. Human fibrinogen plays a
pivotal role in blood clotting and tissue healing. ProFibrix is led by a team
with extensive commercial, clinical and scientific experience in the
hemostasis field. Fibrocaps, the company's lead product, is based on a mixture
of fibrinogen and thrombin and is a unique dry powder topical tissue sealant
that stops acute and severe bleeding after trauma injury or during surgery.
Fibrocaps has major advantages over existing liquid tissue sealants: It is
easier to prepare and use, is more stable and effective, and can be applied in
various ways, including in sprays or bandages. To support the development of
its pipeline, ProFibrix is establishing a recombinant fibrinogen production
platform in human PER.C6(R) cells that is expected to go into GMP production
in 2010.





For further information:

For further information: ProFibrix B.V., Jaap Koopman, PhD, CEO, Tel: +
31(0)6-21628475, E-mail: j.koopman@profibrix.com; ProFibrix Inc., Jan Ohrstrom
MD, COO, Tel: + (0)2069105404, E-mail: j.ohrstrom@profibrix.com

Organization Profile

PROFIBRIX

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890